IFP Advisors Inc Has $29,000 Stake in Recursion Pharmaceuticals, Inc. $RXRX

IFP Advisors Inc lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 63.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,705 shares of the company’s stock after selling 10,103 shares during the period. IFP Advisors Inc’s holdings in Recursion Pharmaceuticals were worth $29,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Clear Creek Financial Management LLC boosted its position in Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock valued at $113,000 after buying an additional 1,907 shares in the last quarter. GAMMA Investing LLC grew its holdings in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Recursion Pharmaceuticals by 16.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock valued at $78,000 after acquiring an additional 2,219 shares during the period. QRG Capital Management Inc. raised its stake in shares of Recursion Pharmaceuticals by 8.5% during the first quarter. QRG Capital Management Inc. now owns 28,515 shares of the company’s stock valued at $151,000 after acquiring an additional 2,244 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Recursion Pharmaceuticals by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,864 shares of the company’s stock worth $163,000 after purchasing an additional 2,587 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares of the company’s stock, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.43% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.25.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $5.75 on Thursday. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company’s fifty day moving average is $5.17 and its 200 day moving average is $5.16. The stock has a market cap of $2.50 billion, a PE ratio of -3.23 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter last year, the firm earned ($0.40) EPS. The business’s revenue was up 33.3% on a year-over-year basis. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.